Genetic Variants in Leukemias: Current Insights into Treatment Outcomes

Overview

Journal Pharmgenomics Pers Med

Publisher Dove Medical Press

Date 2017 May 27

PMID 28546766

Citations 11

Authors

Ravindran Ankathil

Affiliations

Soon will be listed here.

Abstract

Despite improvements in treatment of different types of leukemia, not all patients respond optimally for a particular treatment. Some treatments will work better for some, while being harmful or ineffective for others. This is due to genetic variation in the form of single-nucleotide polymorphisms (SNPs) that affect gene expression or function and cause inherited interindividual differences in the metabolism and disposition of drugs. Drug transporters are one of the determinants governing the pharmacokinetic profile of chemotherapeutic drugs. The transporter gene transports a wide range of drugs, including drugs used in leukemia treatment. Polymorphisms in the gene do affect intrinsic resistance and pharmacokinetics of several drugs used in leukemia treatment protocols and thereby affect the efficacy of treatment and event-free survival. This review focuses on the impact of three commonly occurring SNPs (1236C>T, 2677G>T/A, and 3435C>T) of on treatment response of various types of leukemia. From the literature available, some of the genotypes and haplotypes of these SNPs have been found to be potential determinants of interindividual variability in drug disposition and pharmacologic response in different types of leukemia. However, due to inconsistencies in the results observed across the studies, additional studies, considering novel genomic methodologies, comprehensive definition of clinical phenotypes, adequate sample size, and uniformity in all the confounding factors, are warranted.

Citing Articles

Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients.

Rahmayanti S, Amalia R, Rusdiana T Cancer Chemother Pharmacol. 2024; 94(2):141-155.

PMID: 39002021 DOI: 10.1007/s00280-024-04694-0.

Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer.

Kinnel B, Singh S, Oprea-Ilies G, Singh R Cancers (Basel). 2023; 15(4).

PMID: 36831661 PMC: 9954028. DOI: 10.3390/cancers15041320.

Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia.

Shriyan B, Mehta P, Patil A, Jadhav S, Kumar S, Puri A Eur J Clin Pharmacol. 2022; 78(8):1321-1330.

PMID: 35652931 DOI: 10.1007/s00228-022-03345-8.

High expression levels and the C3435T SNP of the ABCB1 gene are associated with lower survival in adult patients with acute myeloblastic leukemia in Mexico City.

Olarte Carrillo I, Garcia Laguna A, De la Cruz Rosas A, Ramos Penafiel C, Collazo Jaloma J, Martinez Tovar A BMC Med Genomics. 2021; 14(1):251.

PMID: 34702282 PMC: 8549154. DOI: 10.1186/s12920-021-01101-y.

Pharmacogenetics of the Central Nervous System-Toxicity and Relapse Affecting the CNS in Pediatric Acute Lymphoblastic Leukemia.

Sagi J, Gezsi A, Egyed B, Jakab Z, Benedek N, Attarbaschi A Cancers (Basel). 2021; 13(10).

PMID: 34066083 PMC: 8151239. DOI: 10.3390/cancers13102333.

References

Gardner E, Burger H, van Schaik R, van Oosterom A, De Bruijn E, Guetens G . Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther. 2006; 80(2):192-201. DOI: 10.1016/j.clpt.2006.05.003. View

Leith C, Kopecky K, Chen I, Eijdems L, Slovak M, McCONNELL T . Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999; 94(3):1086-99. View

Bodor M, Kelly E, Ho R . Characterization of the human MDR1 gene. AAPS J. 2005; 7(1):E1-5. PMC: 2751491. DOI: 10.1208/aapsj070101. View

Green H, Falk I, Lotfi K, Paul E, Hermansson M, Rosenquist R . Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics J. 2010; 12(2):111-8. DOI: 10.1038/tpj.2010.79. View

Eadie L, Dang P, Saunders V, Yeung D, Osborn M, Grigg A . The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia. 2016; 31(1):75-82. DOI: 10.1038/leu.2016.179. View

Jamroziak K, Mlynarski W, Balcerczak E, Mistygacz M, Trelinska J, Mirowski M . Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004; 72(5):314-21. DOI: 10.1111/j.1600-0609.2004.00228.x. View

Dawidowska M, Kosmalska M, Sedek L, Szczepankiewicz A, Twardoch M, Sonsala A . Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL. Sci Rep. 2016; 6:29427. PMC: 4947903. DOI: 10.1038/srep29427. View

Ni L, Li J, Miao K, Qiao C, Zhang S, Qiu H . Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol. 2010; 28(1):265-9. DOI: 10.1007/s12032-010-9456-9. View

Hodges L, Markova S, Chinn L, Gow J, Kroetz D, Klein T . Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2010; 21(3):152-61. PMC: 3098758. DOI: 10.1097/FPC.0b013e3283385a1c. View

10.

Fromm M . Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004; 25(8):423-9. DOI: 10.1016/j.tips.2004.06.002. View

11.

Hochhaus A, OBrien S, Guilhot F, Druker B, Branford S, Foroni L . Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23(6):1054-61. DOI: 10.1038/leu.2009.38. View

12.

Kroetz D, Pauli-Magnus C, Hodges L, Huang C, Kawamoto M, Johns S . Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics. 2003; 13(8):481-94. DOI: 10.1097/00008571-200308000-00006. View

13.

Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris S, Ramsay M . Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity. Pharmacogenomics. 2011; 12(12):1663-70. DOI: 10.2217/pgs.11.106. View

14.

Cascorbi I . Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther. 2006; 112(2):457-73. DOI: 10.1016/j.pharmthera.2006.04.009. View

15.

Hoffmeyer S, Burk O, von Richter O, Arnold H, Brockmoller J, Johne A . Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000; 97(7):3473-8. PMC: 16264. DOI: 10.1073/pnas.97.7.3473. View

16.

Marchetti S, Mazzanti R, Beijnen J, Schellens J . Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007; 12(8):927-41. DOI: 10.1634/theoncologist.12-8-927. View

17.

Megias-Vericat J, Rojas L, Herrero M, Boso V, Montesinos P, Moscardo F . Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015; 15(2):109-18. DOI: 10.1038/tpj.2014.80. View

18.

Relling M, Dervieux T . Pharmacogenetics and cancer therapy. Nat Rev Cancer. 2002; 1(2):99-108. DOI: 10.1038/35101056. View

19.

Gurney H, Wong M, Balleine R, Rivory L, McLachlan A, Hoskins J . Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther. 2007; 82(1):33-40. DOI: 10.1038/sj.clpt.6100201. View

20.

Marzolini C, Paus E, Buclin T, Kim R . Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004; 75(1):13-33. DOI: 10.1016/j.clpt.2003.09.012. View